Medpace Holdings Inc (NASDAQ:MEDP) has earned an average rating of “Hold” from the ten analysts that are covering the firm, Marketbeat Ratings reports. Seven investment analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $37.40.
Several equities research analysts have issued reports on MEDP shares. Credit Suisse Group restated an “outperform” rating and issued a $42.00 price target (up from $41.00) on shares of Medpace in a report on Tuesday, February 27th. Zacks Investment Research upgraded Medpace from a “hold” rating to a “buy” rating and set a $40.00 price target for the company in a report on Wednesday, December 13th. Jefferies Group restated a “hold” rating and issued a $35.00 price target on shares of Medpace in a report on Thursday, March 1st. Wells Fargo & Co lowered their price target on Medpace from $38.00 to $35.00 and set a “market perform” rating for the company in a report on Wednesday, February 28th. Finally, BidaskClub upgraded Medpace from a “buy” rating to a “strong-buy” rating in a report on Friday, February 16th.
Medpace (MEDP) opened at $36.67 on Friday. Medpace has a one year low of $21.76 and a one year high of $39.64. The company has a quick ratio of 0.67, a current ratio of 0.67 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $1,250.49, a PE ratio of 37.42, a price-to-earnings-growth ratio of 1.44 and a beta of 0.50.
Medpace (NASDAQ:MEDP) last released its earnings results on Monday, February 26th. The company reported $0.39 earnings per share for the quarter, beating the consensus estimate of $0.38 by $0.01. Medpace had a return on equity of 10.55% and a net margin of 8.97%. The firm had revenue of $99.45 million for the quarter, compared to analyst estimates of $97.25 million. During the same quarter in the prior year, the firm posted $0.35 earnings per share. The company’s quarterly revenue was up 4.3% on a year-over-year basis. equities research analysts expect that Medpace will post 1.88 EPS for the current fiscal year.
Institutional investors have recently made changes to their positions in the business. MetLife Investment Advisors LLC bought a new position in shares of Medpace during the fourth quarter worth about $137,000. SG Americas Securities LLC bought a new position in shares of Medpace during the fourth quarter worth about $151,000. We Are One Seven LLC bought a new position in shares of Medpace during the fourth quarter worth about $211,000. Atria Investments LLC bought a new position in shares of Medpace during the fourth quarter worth about $211,000. Finally, Koch Industries Inc. bought a new position in shares of Medpace during the fourth quarter worth about $279,000. Institutional investors own 23.50% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Medpace Holdings Inc (MEDP) Given Average Recommendation of “Hold” by Brokerages” was first posted by Enterprise Leader and is owned by of Enterprise Leader. If you are reading this news story on another website, it was illegally copied and reposted in violation of international copyright & trademark laws. The original version of this news story can be read at https://theenterpriseleader.com/2018/04/02/medpace-holdings-inc-medp-given-average-recommendation-of-hold-by-brokerages.html.
Medpace Holdings, Inc is a clinical contract research organization. The Company provides clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company’s drug development services focus on full service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support.
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.